Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways.

ABSTRACT: Although trisomy 12 (+12) chronic lymphocytic leukemia (CLL) comprises about 20% of cases, relatively little is known about its pathophysiology. These cases often demonstrate atypical morphological and immunophenotypic features, high proliferative rates, unmutated immunoglobulin heavy chain variable region genes, and a high frequency of NOTCH1 mutation. Patients with +12 CLL have an intermediate prognosis, and show higher incidences of thrombocytopenia, Richter transformation, and other secondary cancers. Despite these important differences, relatively few transcriptional profiling studies have focused on identifying dysregulated pathways that characterize +12 CLL, and most have used a hierarchical cytogenetic classification in which cases with more than one recurrent abnormality ar

SUBMITTER: Abruzzo LV 

PROVIDER: S-EPMC6269288 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature